TSKU

Summary

TSKU (tsukushi, small leucine rich proteoglycan, HGNC:28850) is a protein-coding gene on chromosome 11q13.5, encoding Tsukushi (Q8WUA8). Contributes to various developmental events and other processes such as wound healing and cholesterol homeostasis through its interactions with multiple signaling pathways.

Predicted to enable transforming growth factor beta binding activity. Predicted to be involved in several processes, including cholesterol efflux; cholesterol homeostasis; and nervous system development. Predicted to act upstream of or within several processes, including ciliary body morphogenesis; negative regulation of Wnt signaling pathway; and telencephalon development. Predicted to be located in extracellular region. Predicted to be active in extracellular space.

Source: NCBI Gene 25987 — RefSeq curated summary.

At a glance

• GWAS associations: 6
• Clinical variants (ClinVar): 66 total
• MANE Select transcript: NM_015516

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:28850
Approved symbol	TSKU
Name	tsukushi, small leucine rich proteoglycan
Location	11q13.5
Locus type	gene with protein product
Status	Approved
Aliases	E2IG4, TSK
Ensembl gene	ENSG00000182704
Ensembl biotype	protein_coding
OMIM	608015
Entrez	25987

Gene structure

Transcript identifiers

Ensembl transcripts: 16 — 16 protein_coding

ENST00000333090, ENST00000525167, ENST00000527881, ENST00000533752, ENST00000612930, ENST00000870292, ENST00000870293, ENST00000870294, ENST00000870295, ENST00000870296, ENST00000870297, ENST00000870298, ENST00000870299, ENST00000870300, ENST00000956905, ENST00000956906

RefSeq mRNA: 5 — MANE Select: NM_015516 NM_001258210, NM_001318477, NM_001318478, NM_001318479, NM_015516

CCDS: CCDS8246

Canonical transcript exons

ENST00000333090 — 2 exons

Exon	Start	End
ENSE00001304798	76783356	76783404
ENSE00002201219	76795609	76798144

Expression profiles

Bgee: expression breadth ubiquitous, 242 present calls, max score 98.50.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 16.4636 / max 314.7449, expressed in 1588 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
115962	9.1746	1552
115963	7.0457	1254
206392	0.1455	46
115959	0.0977	48

Top tissues by expression

272 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
decidua	UBERON:0002450	98.50	gold quality
endocervix	UBERON:0000458	97.89	gold quality
ectocervix	UBERON:0012249	97.56	gold quality
left uterine tube	UBERON:0001303	95.72	gold quality
mucosa of stomach	UBERON:0001199	95.50	gold quality
right lobe of liver	UBERON:0001114	95.20	gold quality
lower esophagus mucosa	UBERON:0035834	94.78	gold quality
subcutaneous adipose tissue	UBERON:0002190	94.63	gold quality
vagina	UBERON:0000996	94.21	gold quality
skin of abdomen	UBERON:0001416	94.00	gold quality
tibial nerve	UBERON:0001323	93.73	gold quality
skin of leg	UBERON:0001511	93.48	gold quality
vena cava	UBERON:0004087	93.40	gold quality
mammalian vulva	UBERON:0000997	93.32	gold quality
liver	UBERON:0002107	93.30	gold quality
esophagus mucosa	UBERON:0002469	93.23	gold quality
omental fat pad	UBERON:0010414	92.96	gold quality
peritoneum	UBERON:0002358	92.94	gold quality
adipose tissue of abdominal region	UBERON:0007808	92.87	gold quality
adipose tissue	UBERON:0001013	92.84	gold quality
zone of skin	UBERON:0000014	92.42	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	92.28	gold quality
right ovary	UBERON:0002118	92.07	gold quality
connective tissue	UBERON:0002384	91.88	gold quality
uterine cervix	UBERON:0000002	91.56	gold quality
left coronary artery	UBERON:0001626	91.51	gold quality
coronary artery	UBERON:0001621	91.28	gold quality
right lobe of thyroid gland	UBERON:0001119	91.26	gold quality
synovial joint	UBERON:0002217	90.97	gold quality
left lobe of thyroid gland	UBERON:0001120	90.95	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-CURD-10	no	110.07
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

90 targeting TSKU, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4747-5P	100.00	67.90	2681
HSA-MIR-5196-5P	100.00	67.98	2761
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-6870-5P	99.99	68.55	2115
HSA-MIR-520G-5P	99.99	66.76	658
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-6780B-5P	99.96	69.60	2562
HSA-MIR-4725-3P	99.96	69.53	2520
HSA-MIR-2110	99.96	66.68	1930
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-96-5P	99.95	72.80	2140
HSA-MIR-5010-5P	99.94	64.11	705
HSA-MIR-4525	99.94	64.38	675
HSA-MIR-12133	99.92	71.82	2006
HSA-MIR-1271-5P	99.91	71.99	1972
HSA-MIR-106A-5P	99.90	73.94	2683
HSA-MIR-124-3P	99.89	73.74	3043
HSA-MIR-506-3P	99.89	73.55	3057
HSA-MIR-6783-3P	99.89	67.92	2059
HSA-MIR-1343-3P	99.89	66.78	1815
HSA-MIR-17-5P	99.89	73.83	2665
HSA-MIR-4271	99.88	68.32	2244
HSA-MIR-605-3P	99.88	69.22	1833
HSA-MIR-6780A-5P	99.88	66.69	2776
HSA-MIR-106B-5P	99.88	74.72	2795
HSA-MIR-20A-5P	99.88	74.76	2769
HSA-MIR-20B-5P	99.88	74.01	2621
HSA-MIR-519D-3P	99.88	73.97	2607

Literature-anchored findings (GeneRIF, showing 9)

• The spatio-temporal expression of Decorin, Semaphorin6D, SPARC, Spry-1 and Tsukushi in developing prostate is described and observed similar mesenchymal expression patterns in rat and human. (PMID:22880013)
• TSK controls the hair cycle by regulating TGF-beta1 signaling. (PMID:22995554)
• Among its predicted target genes down-regulated by miR-2110, knockdown of Tsukushi (TSKU) expression showed the most potent effect in inducing cell differentiation and reducing cell survival, suggesting that TSKU protein plays a key role in mediating the functions of miR-2110. Low tumor miR-2110 levels were significantly correlated with high tumor TSKU mRNA levels. (PMID:30550571)
• in lung cancer cells, TSK is expressed more highly than the other small leucine-rich repeat proteoglycan family members, and regulates the epithelial-mesenchymal transition and cell proliferation (PMID:31027686)
• The hepatokine Tsukushi is released in response to NAFLD and impacts cholesterol homeostasis. (PMID:31391339)
• Gastric banding-associated weight loss diminishes hepatic Tsukushi expression. (PMID:32442908)
• Elevated Serum Tsukushi Levels in Patients With Hyperthyroidism. (PMID:33117292)
• Novel roles of Tsukushi in signaling pathways and multiple disease processes. (PMID:33759220)
• Tsukushi and TSKU genotype in obesity and related metabolic disorders. (PMID:33860453)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	tsku	ENSDARG00000040815
mus_musculus	Tsku	ENSMUSG00000049580
rattus_norvegicus	Tsku	ENSRNOG00000027784

Paralogs (22): IGFALS (ENSG00000099769), TLR8 (ENSG00000101916), LRRC17 (ENSG00000128606), RXFP2 (ENSG00000133105), CD180 (ENSG00000134061), TLR4 (ENSG00000136869), TLR2 (ENSG00000137462), LRRC32 (ENSG00000137507), LRRC3 (ENSG00000160233), LRRC53 (ENSG00000162621), TLR3 (ENSG00000164342), VASN (ENSG00000168140), RXFP1 (ENSG00000171509), NRROS (ENSG00000174004), TLR10 (ENSG00000174123), TLR1 (ENSG00000174125), TLR6 (ENSG00000174130), LRRC3B (ENSG00000179796), TLR5 (ENSG00000187554), TLR7 (ENSG00000196664), LRIT2 (ENSG00000204033), LRRC3C (ENSG00000204913)

Protein

Protein identifiers

Tsukushi — Q8WUA8 (reviewed: Q8WUA8)

Alternative names: E2-induced gene 4 protein, Leucine-rich repeat-containing protein 54

All UniProt accessions (3): Q8WUA8, E9PLG7, E9PN12

UniProt curated annotations — full annotation on UniProt →

Function. Contributes to various developmental events and other processes such as wound healing and cholesterol homeostasis through its interactions with multiple signaling pathways. Wnt signaling inhibitor which competes with WNT2B for binding to Wnt receptor FZD4 and represses WNT2B-dependent development of the peripheral eye. Plays a role in regulating the hair cycle by controlling TGFB1 signaling. Required for the development of the anterior commissure in the brain by inhibiting neurite outgrowth. Essential for terminal differentiation of hippocampal neural stem cells. Plays a role in regulating bone elongation and bone mass by modulating growth plate chondrocyte function and overall body size. Required for development of the inner ear through its involvement in stereocilia formation in inner hair cells. Facilitates wound healing by inhibiting secretion of TGFB1 from macrophages which prevents myofibroblast differentiation, maintaining inflammatory cell quiescence. Plays a role in cholesterol homeostasis by reducing circulating high-density lipoprotein cholesterol, lowering cholesterol efflux capacity and decreasing cholesterol-to-bile acid conversion in the liver. In one study, shown to negatively regulate sympathetic innervation in brown fat, leading to reduced energy expenditure. In another study, shown not to affect brown fat thermogenic capacity, body weight gain or glucose homeostasis.

Subunit / interactions. Interacts with FZD4 (via FZ domain); competes with WNT2B for binding to FZD4, inhibiting Wnt signaling and repressing peripheral eye development. Interacts with TGFB1; the interaction contributes to regulation of the hair cycle. Interacts with netrin. Interacts with CCN2.

Subcellular location. Secreted.

Induction. By 17-beta-estradiol.

Miscellaneous. This factor is named ‘Tsukushi’ because its expression pattern in chick embryos is similar to the shape of the Japanese horsetail plant, tsukushi.

RefSeq proteins (5): NP_001245139, NP_001305406, NP_001305407, NP_001305408, NP_056331* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001611	Leu-rich_rpt	Repeat
IPR003591	Leu-rich_rpt_typical-subtyp	Repeat
IPR032675	LRR_dom_sf	Homologous_superfamily

Pfam: PF00560, PF13855

UniProt features (20 total): repeat 10, sequence variant 4, glycosylation site 2, signal peptide 1, chain 1, sequence conflict 1, domain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8WUA8-F1	86.55	0.62

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Glycosylation sites (2): 74, 137

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 257 (showing top): GOBP_CARTILAGE_DEVELOPMENT, GOBP_SKELETAL_SYSTEM_DEVELOPMENT, GOBP_STEROL_HOMEOSTASIS, GOBP_GROWTH, GOBP_NEUROGENESIS, TAL1ALPHAE47_01, GOBP_REGULATION_OF_WNT_SIGNALING_PATHWAY, GOBP_CHONDROCYTE_DEVELOPMENT, GOBP_REGULATION_OF_HAIR_CYCLE, CAGGTCC_MIR492, GOBP_VENTRICULAR_SYSTEM_DEVELOPMENT, GOBP_BONE_GROWTH, chr11q13, GOBP_FOREBRAIN_DEVELOPMENT, GOBP_ORGANIC_HYDROXY_COMPOUND_TRANSPORT

GO Biological Process (24): growth plate cartilage chondrocyte development (GO:0003431), immune response (GO:0006955), transforming growth factor beta receptor signaling pathway (GO:0007179), cholesterol metabolic process (GO:0008203), regulation of gene expression (GO:0010468), negative regulation of neuron projection development (GO:0010977), corpus callosum morphogenesis (GO:0021540), lateral ventricle development (GO:0021670), hippocampus development (GO:0021766), anterior commissure morphogenesis (GO:0021960), negative regulation of Wnt signaling pathway (GO:0030178), negative regulation of transforming growth factor beta1 production (GO:0032911), cholesterol efflux (GO:0033344), wound healing (GO:0042060), cholesterol homeostasis (GO:0042632), positive regulation of hair cycle (GO:0042635), camera-type eye development (GO:0043010), inner ear receptor cell stereocilium organization (GO:0060122), ciliary body morphogenesis (GO:0061073), energy homeostasis (GO:0097009), bone growth (GO:0098868), negative regulation of myofibroblast differentiation (GO:1904761), nervous system development (GO:0007399), anatomical structure morphogenesis (GO:0009653)

GO Molecular Function (3): transforming growth factor beta binding (GO:0050431), protein binding (GO:0005515), cytokine binding (GO:0019955)

GO Cellular Component (2): obsolete extracellular space (GO:0005615), extracellular region (GO:0005576)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
neuron projection development	2
central nervous system projection neuron axonogenesis	2
telencephalon development	2
anatomical structure development	2
growth plate cartilage chondrocyte differentiation	1
chondrocyte development involved in endochondral bone morphogenesis	1
immune system process	1
response to stimulus	1
cellular response to transforming growth factor beta stimulus	1
transforming growth factor beta receptor superfamily signaling pathway	1
sterol metabolic process	1
secondary alcohol metabolic process	1
gene expression	1
regulation of macromolecule biosynthetic process	1
regulation of neuron projection development	1
negative regulation of cell projection organization	1
corpus callosum development	1
ventricular system development	1
pallium development	1
limbic system development	1
negative regulation of signal transduction	1
Wnt signaling pathway	1
regulation of Wnt signaling pathway	1
transforming growth factor beta1 production	1
regulation of transforming growth factor beta1 production	1
negative regulation of transforming growth factor beta production	1
cholesterol transport	1
response to wounding	1
tissue regeneration	1
sterol homeostasis	1
hair cycle	1
regulation of hair cycle	1
positive regulation of multicellular organismal process	1
eye development	1
inner ear receptor cell development	1
anatomical structure morphogenesis	1
camera-type eye morphogenesis	1
multicellular organismal-level homeostasis	1
growth factor binding	1
cytokine binding	1

Protein interactions and networks

STRING

1016 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TSKU	CHRD	Q9H2X0	834
TSKU	FZD4	Q9ULV1	710
TSKU	ACER3	Q9NUN7	542
TSKU	CCDC201	A0A1B0GTI1	526
TSKU	BMP4	P12644	492
TSKU	TGFB1	P01137	478
TSKU	FGF8	P55075	470
TSKU	D6RC18	D6RC18	459
TSKU	PDE4C	Q08493	459
TSKU	ZSCAN2	Q7Z7L9	454
TSKU	OPTC	Q9UBM4	445
TSKU	TBRG1	Q3YBR2	439
TSKU	STOML1	Q9UBI4	425
TSKU	EPDR1	Q9UM22	406
TSKU	OMD	Q99983	404

IntAct

8 interactions, top by confidence:

A	B	Type	Score
SKIL	TSKU	psi-mi:“MI:0915”(physical association)	0.370
UXS1	IPO7	psi-mi:“MI:0914”(association)	0.350
	SHTN1	psi-mi:“MI:0914”(association)	0.350
UXS1	HRAS	psi-mi:“MI:0914”(association)	0.350
UXS1	PDE2A	psi-mi:“MI:0914”(association)	0.350
SLC30A5	NBAS	psi-mi:“MI:0914”(association)	0.350

BioGRID (9): TSKU (Affinity Capture-MS), TSKU (Affinity Capture-MS), TSKU (Affinity Capture-MS), TSKU (Proximity Label-MS), TSKU (Protein-peptide), TSKU (Affinity Capture-MS), TSKU (Cross-Linking-MS (XL-MS)), TSKU (Affinity Capture-MS), TSKU (Two-hybrid)

ESM2 similar proteins: A1A4H9, A4IFA6, A6NDA9, E7FE13, G3XA59, O08644, O08742, O08770, O14498, O15197, P0C0K6, P0C0K7, P35590, P40197, P59383, Q06805, Q06806, Q14392, Q149C3, Q3ZBI5, Q5JZY3, Q5NVQ6, Q5R6B1, Q5RF01, Q5RKR3, Q6EMK4, Q6GU68, Q6P7C4, Q6PFC5, Q6QMY6, Q6UXK2, Q6UY18, Q80ZD5, Q86UE6, Q86WK7, Q86YC3, Q8BGX3, Q8BYG9, Q8C2S7, Q8CBR6

Diamond homologs: A3KNN3, A4IFA6, A4IIW9, A6H789, A6H793, A6NJW4, A8WHP9, C3YZ59, E5DHB5, F7D3V9, G5EFX6, O14498, O35367, O46542, O60938, O62702, O75093, O75094, O75473, O88186, O88279, O88280, O94813, P07585, P14770, P21793, P24014, P28654, P28675, P59034, P59035, P70193, Q01129, Q13641, Q28888, Q29393, Q3SXY7, Q3ZBN5, Q45R42, Q4KLL3

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

66 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	58
Likely benign	6
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

356 predictions. Top by Δscore:

Variant	Effect	Δscore
11:76795607:A:AG	acceptor_gain	1.0000
11:76795608:G:GG	acceptor_gain	1.0000
11:76793801:GGG:G	donor_gain	0.9900
11:76793802:GGG:G	donor_gain	0.9900
11:76795603:TTCTA:T	acceptor_loss	0.9900
11:76795604:TCTA:T	acceptor_loss	0.9900
11:76795605:CTA:C	acceptor_loss	0.9900
11:76795606:TAG:T	acceptor_loss	0.9900
11:76795608:G:A	acceptor_loss	0.9900
11:76793803:G:T	donor_gain	0.9800
11:76795608:GC:G	acceptor_gain	0.9800
11:76795608:GCC:G	acceptor_gain	0.9800
11:76795608:GCCC:G	acceptor_gain	0.9800
11:76795608:GCCCC:G	acceptor_gain	0.9800
11:76782430:CAAG:C	donor_loss	0.9700
11:76782431:AAGG:A	donor_loss	0.9700
11:76782433:GGTA:G	donor_loss	0.9700
11:76793798:A:T	donor_gain	0.9700
11:76783404:GGT:G	donor_loss	0.9500
11:76783405:G:T	donor_loss	0.9500
11:76783406:T:G	donor_loss	0.9500
11:76784707:GA:G	donor_gain	0.9500
11:76784708:A:G	donor_gain	0.9300
11:76792409:T:G	donor_gain	0.9100
11:76792701:C:A	acceptor_gain	0.9100
11:76782835:T:TA	donor_gain	0.8900
11:76782836:A:AA	donor_gain	0.8900
11:76784653:G:GT	donor_gain	0.8900
11:76783407:GAGT:G	donor_loss	0.8800
11:76793752:G:GT	acceptor_gain	0.8700

AlphaMissense

2240 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
11:76795888:T:C	L91P	0.993
11:76795725:T:C	F37L	0.992
11:76795727:C:A	F37L	0.992
11:76795727:C:G	F37L	0.992
11:76795747:G:A	C44Y	0.992
11:76795748:T:G	C44W	0.991
11:76795804:T:C	L63S	0.991
11:76795746:T:A	C44S	0.989
11:76795747:G:C	C44S	0.989
11:76795810:T:C	L65P	0.989
11:76795898:C:A	N94K	0.989
11:76795898:C:G	N94K	0.989
11:76795960:T:C	L115P	0.989
11:76795692:T:A	C26S	0.987
11:76795693:G:C	C26S	0.987
11:76795746:T:C	C44R	0.987
11:76795882:T:C	L89P	0.987
11:76795888:T:A	L91H	0.987
11:76795686:T:A	C24S	0.986
11:76795687:G:C	C24S	0.986
11:76796117:C:A	N167K	0.986
11:76796117:C:G	N167K	0.986
11:76796029:T:C	L138P	0.985
11:76795717:T:G	F34C	0.984
11:76795722:A:C	S36R	0.984
11:76795724:C:A	S36R	0.984
11:76795724:C:G	S36R	0.984
11:76795954:T:A	L113H	0.984
11:76795716:T:C	F34L	0.983
11:76795718:C:A	F34L	0.983

dbSNP variants (sampled 300 via entrez): RS1000116931 (11:76783363 C>T), RS1000204734 (11:76788733 T>C), RS1000352507 (11:76795280 C>T), RS1000629388 (11:76794623 C>G), RS1000861856 (11:76784495 C>T), RS1000923587 (11:76790075 A>G), RS1001016704 (11:76789714 T>A,C,G), RS1001103322 (11:76784131 C>A,T), RS1001209889 (11:76790233 A>G), RS1001245882 (11:76785442 G>A), RS1001467160 (11:76797480 G>A,C), RS1001756036 (11:76796401 C>A,T), RS1002041133 (11:76780733 G>A,C), RS1002096572 (11:76780435 T>C), RS1002097601 (11:76785282 A>C)

Disease associations

OMIM: gene MIM:608015 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

6 associations (top):

Study	Trait	p-value
GCST007401_26	Factor VII activity	1.000000e-10
GCST007401_7	Factor VII activity	2.000000e-10
GCST009798_77	Asthma	4.000000e-35
GCST009798_82	Asthma	2.000000e-45
GCST010988_422	Adult body size	5.000000e-08
GCST90000514_17	Gastroesophageal reflux disease	1.000000e-08

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004619	factor VII measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

54 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation, decreases expression, increases expression	8
Estradiol	affects reaction, increases reaction, decreases reaction, increases expression, decreases expression (+1 more)	5
Tetrachlorodibenzodioxin	decreases expression, increases expression, affects expression, affects binding, increases reaction	5
bisphenol A	increases expression, affects expression	4
sodium arsenite	increases abundance, increases expression, decreases expression	3
Genistein	increases expression	3
graphene oxide	increases expression	2
Rifampin	increases expression	2
Tobacco Smoke Pollution	decreases expression, increases expression	2
Cyclosporine	decreases expression, increases expression	2
Aflatoxin B1	affects expression, decreases expression	2
aristolochic acid I	decreases expression	1
pirinixic acid	affects binding, increases activity, increases expression	1
tris(2-butoxyethyl) phosphate	affects expression	1
o,p’-DDT	increases expression	1
afimoxifene	decreases reaction, increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
butyraldehyde	decreases expression	1
9,10-dihydro-9,10-dihydroxybenzo(a)pyrene	increases expression	1
beta-methylcholine	affects expression	1
brequinar	increases expression	1
CGP 52608	affects binding, increases reaction	1
chloropicrin	decreases expression	1
corosolic acid	increases expression	1
ICG 001	increases expression	1
abrine	decreases expression	1
jinfukang	affects cotreatment, increases expression	1
picoxystrobin	decreases expression	1
(+)-JQ1 compound	decreases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.